The Overview
Bristol Myers Squibb’s (BMS’s) Phase III EXCALIBER-RRMM study of Zenbexus (iberdomide) has significantly improved progression-free survival (PFS) in patients with multiple myeloma (MM). The trial achieved its dual-primary endpoint, demonstrating a median PFS of 42 months for Zenbexus compared to 20 months for the daratumumab, bortezomib, and dexamethasone (DVd) regimen, representing a 51% reduction in the risk of disease progression or death. This success builds on the previously met minimal residual disease (MRD)-negative complete response endpoint, which led to the US FDA's accelerated approval of Zenbexus for relapsed/refractory MM on August 13, 2026. The drug's safety profile remained consistent with prior findings.
Knolens Analysis
At a Glance
| Indication | Multiple myeloma |
| Drug | Iberdomide |
| Company | Bristol Myers Squibb |
| Trial Phase | Phase III |
| Trial Acronym | EXCALIBER-RRMM |
| NCT ID | NCT04975997 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Hematology |
| Comparator | daratumumab, bortezomib and dexamethasone (DVd) |
| Median PFS (Zenbexus) | 42 months |
| Median PFS (Comparator) | 20 months |
| Risk Reduction | 51% |
| FDA Approval Date | August 13, 2026 |
| Approved Indication | relapsed/refractory (R/R) MM |
| Regulatory Milestone | First time MRD used for accelerated approval in MM |
| Conference Name | 68th Annual Meeting of the American Society of Hematology |
| US New MM Cases Annually | More than 35,000 |
| Multiple Myeloma Market Projection | $29bn in 2032 |
BMS's Zenbexus Doubles PFS in Multiple Myeloma, Securing Dual Endpoint Success
Bristol Myers Squibb’s (BMS’s) Phase III EXCALIBER-RRMM study of Zenbexus (iberdomide) has significantly improved progression-free survival (PFS) in patients with multiple myeloma (MM). The trial achieved its dual-primary endpoint, demonstrating a median PFS of 42 months for Zenbexus compared to 20 months for the daratumumab, bortezomib, and dexamethasone (DVd) regimen, representing a 51% reduction in the risk of disease progression or death. This success builds on the previously met minimal residual disease (MRD)-negative complete response endpoint, which led to the US FDA's accelerated approval of Zenbexus for relapsed/refractory MM on August 13, 2026. The drug's safety profile remained consistent with prior findings.
- The EXCALIBER-RRMM study demonstrated a statistically significant improvement in progression-free survival (PFS) for Zenbexus, achieving a median PFS of 42 months compared to 20 months for the DVd regimen. This translates to a 51% reduction in the risk of disease progression or death, successfully meeting the trial's second dual-primary endpoint with robust efficacy data.
- Zenbexus previously secured US FDA accelerated approval for relapsed/refractory (R/R) MM on August 13, 2026, based on the achievement of its other dual-primary endpoint: minimal residual disease (MRD)-negative complete response. This approval marked a significant regulatory milestone, as it was the first time MRD was utilized as an intermediate endpoint for accelerated approval in multiple myeloma.
- Dr. Cristian Massacesi, CMO of BMS, emphasized that these results reinforce Zenbexus's clinical value as an effective oral treatment option for R/R MM, highlighting its potential for use in diverse care settings, including community practices. The full, detailed results from the EXCALIBER-RRMM study are slated for presentation at the 68th Annual Meeting of the American Society of Hematology in December.
- The multiple myeloma market presents substantial commercial potential, with over 35,000 new cases diagnosed annually in the US. GlobalData analysis projects the global multiple myeloma market to grow to $29 billion by 2032 across eight major markets, with the US expected to remain the dominant region, underscoring the significant need for effective new therapies.
Frequently Asked Questions
What is the mechanism of action of Iberdomide in multiple myeloma?
Iberdomide is a novel cereblon E3 ligase modulator (CELMoD) that induces potent degradation of Aiolos and Ikaros, two key transcription factors involved in B-cell development and multiple myeloma cell survival. This degradation leads to direct tumoricidal activity, immune modulation, and inhibition of angiogenesis. Its distinct binding profile to cereblon contributes to its enhanced potency compared to earlier IMiDs.
Which patient populations are most likely to benefit from Iberdomide therapy for multiple myeloma?
Iberdomide is being investigated for patients with relapsed and refractory multiple myeloma, particularly those who have received multiple prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Its efficacy in heavily pretreated populations suggests a potential role in later-line settings. The drug aims to address unmet needs in patients with limited remaining treatment options.
What are the key safety considerations for Iberdomide in multiple myeloma treatment?
Key safety considerations for Iberdomide include myelosuppression, particularly neutropenia and thrombocytopenia, which require careful monitoring and management. Gastrointestinal adverse events such as diarrhea and nausea are also commonly observed. Peripheral neuropathy, a known class effect of IMiDs, should also be monitored, though its incidence and severity may differ from other agents.
How does Iberdomide differentiate from other immunomodulatory drugs (IMiDs) in multiple myeloma?
Iberdomide differentiates from earlier IMiDs like thalidomide, lenalidomide, and pomalidomide through its enhanced binding affinity to cereblon, leading to more potent and rapid degradation of Aiolos and Ikaros. This improved CELMoD activity translates to greater anti-myeloma efficacy, particularly in cells resistant to older IMiDs. Its distinct pharmacological profile offers a new therapeutic option for patients with advanced disease.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
